Table 2.
Motor behavior of MPTP-treated macaques before (OFF score) and after (ON score) l-DOPA and Ro 65–6570 administration
| OFF score | ON score |
|||
|---|---|---|---|---|
| Saline | Ro 65–6570 0.001 mg/kg | Ro 65–6570 0.01 mg/kg | ||
| Chorea | 0.0 ± 0.0 | 23.8 ± 3.3 | 16.8 ± 3.5 | 15.4 ± 4.1 |
| Dystonia | 0.0 ± 0.0 | 23.8 ± 3.3 | 15.8 ± 3.6 | 16.0 ± 4.4* |
| Total dyskinesia | 0.0 ± 0.0 | 47.6 ± 6.6 | 32.8 ± 7.1 | 31.4 ± 8.4* |
| Movement | 2.4 ± 2.4 | 39.4 ± 1.9 | 39.4 ± 1.5 | 40.0 ± 1.7 |
| Bradykinesia | 36.0 ± 0.0 | 9.4 ± 1.7 | 8.6 ± 2.2 | 8.6 ± 3.0 |
| Posture | 19.2 ± 2.9 | 7.2 ± 1.5 | 3.6 ± 1.6 | 1.8 ± 1.1* |
| Tremor | 2.4 ± 2.4 | 0.6 ± 0.6 | 1.0 ± 0.5 | 3.2 ± 1.4 |
| Total parkinsonian disability | 103.2 ± 6.1 | 25.8 ± 4.7 | 21.8 ± 4.9 | 21.4 ± 6.2 |
Five stably parkinsonian macaques were made dyskinetic by chronic l-DOPA treatment. Macaques were then challenged with l-DOPA combined with Ro 65–6570 (0.001 and 0.01 mg/kg, i.m.) or saline. Parkinsonian condition was assessed on a parkinsonian nonhuman primate rating scale scoring movement range, bradykinesia, posture, tremor, and total parkinsonian disability (see Materials and Methods). Dyskinetic condition was assessed on a Dyskinesia Disability Scale evaluating choreiform, dystonic, and total dyskinesia movements (see Materials and Methods). Data are means ± means from five animals. Statistical analysis was performed by nonparametric one-way RM ANOVA followed by Dunn's test for multiple comparisons.
*p < 0.05, versus saline.